Research Alliance Corporation III is no longer a search-stage blank check. Two months after listing, the Cayman vehicle signed an all-stock combination with Oak Hill Bio, the English company that licensed Roche's Angelman antisense program and has already dosed the first participant in a sham-controlled Phase 3 study. The investment debate is not whether a target exists. It is whether rugonersen still deserves a premium to trust cash after a same-class Phase 3 miss at Ultragenyx reset what public markets are willing to pay for UBE3A unsilencing.
The financing package is designed to make redemptions almost irrelevant. RA Capital already funded a $45 million simple agreement for future equity inside Oak Hill. A separate $55 million private placement sits at the original offering price. A backstop can replace the entire public float. That structure is why the common still sits above trust cash even after the Angelman class setback. The remaining question is whether the market is paying for a funded late-stage company or merely for a high-probability close into a de-risked cash pile.
At mid-year the trust held $75 million and the stub printed a thin operating profit only because Treasury interest covered formation costs. Management still flagged substantial doubt about continuing as a going concern outside the trust, and it disclosed a material weakness over payables classification. The combination registration is on file. No shareholder meeting date is set. Does the vote, the redemption print, and the next BEACON enrollment update restore a clinical premium, or does the common settle at the cash floor?